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OBJECTIVES The aim of this study was to determine whether perioperative measurements of heart rate
variability (HRV) and cardiac troponin I (cTnI) add additional prognostic information to
established risk scores for first-year mortality in patients at risk of coronary artery disease
(CAD) undergoing major noncardiac surgery.
BACKGROUND In cardiac-risk patients undergoing major noncardiac surgery, the short- and long-term
prognoses are mainly influenced by perioperative cardiac complications. Heart rate variability
and cTnI are important prognostic markers in patients with congestive heart failure and
myocardial infarction.
METHODS In a prospective study, 173 patients with CAD or at high risk of CAD undergoing major
noncardiac surgery were followed up for one year. The main outcome measure was all-cause
mortality. In addition to clinical parameters and established risk scores, HRV and cTnI were
assessed perioperatively.
RESULTS Twenty-eight (16%) patients died within one year. Multivariate logistic regression analysis
revealed three findings that were independently associated with death within the first year
after surgery: the revised cardiac risk index (odds ratio 6.2 [95% confidence interval 1.6 to 25],
depressed HRV before induction of anesthesia (16.2 [2.8 to 94]), and elevation of cTnI on
postoperative day 1 or 2 (9.8 [3.0 to 32]).
CONCLUSION Depressed HRV before induction of anesthesia and elevated cTnI postoperatively are
independent and powerful predictors of one-year mortality for patients at risk of CAD
undergoing major noncardiac surgery and add incremental prognostic information to
established risk scores that only consider preoperative information. (J Am Coll Cardiol
2003;42:1767–76) © 2003 by the American College of Cardiology Foundation
Patients with coronary artery disease (CAD) undergoing
major noncardiac surgery have a substantial risk of peri-
operative morbidity and mortality (1,2), and even their
long-term outcome is compromised (3,4). Several preoper-
ative risk stratification scores have been developed and
adjusted in recent years (5–8). These scores use only the
patient’s history and the preoperative clinical status to
predict short-term morbidity and mortality or to identify
patients with the need for more detailed cardiac testing.
However, patient’s outcome does not depend only on
preoperative findings and the surgery performed, but also on
perioperative events. As none of the established risk scores
consider such perioperative findings and events, a compre-
hensive risk assessment for long-term outcome is lacking.
Perioperative myocardial ischemia is one event strongly
correlated with adverse long-term outcome (3,9,10). Peri-
operative myocardial ischemia occurs in up to 40% of
patients at risk of CAD (10) but is usually clinically silent
(11,12) and, accordingly, difficult to detect. Myocardial
ischemia leading to myocardial cell death can be detected
by specific markers of myocardial cell injury, for example,
cardiac troponin I (cTnI) or T. Their prognostic values
have been shown in nonsurgical patients with acute coro-
nary syndromes (13–15). In surgical patients, cardiac
troponin elevation was shown to detect perioperative
myocardial infarction (16), to predict cardiac complica-
tions (17), and to predict six-month outcome (4,18). De-
pressed heart rate variability (HRV) as a parameter of
the patient’s autonomic function was shown to be another
predictor of future cardiac events, cardiac death, and all-
cause mortality in patients with acute myocardial infarction
and unstable angina (19–23). Reduced HRV was also
strongly associated with congestive heart failure (24–26).
However, its prognostic value in surgical patients was
evaluated only in a small number of patients for short-term
outcome (27).
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The aim of our study was to evaluate whether reduced
HRV and perioperatively elevated levels of cTnI are predic-
tive for long-term mortality and provide additional infor-
mation to established risk scores in patients with docu-
mented CAD or at high risk of CAD undergoing major
noncardiac surgery.
METHODS
Patients. Patients were eligible for the study if they had
definite CAD or were at a high risk of CAD, according to
the criteria listed in Table 1, and had current major
noncardiac surgery: vascular procedures of the abdominal
aorta or the lower limb, open intraperitoneal or intrathoracic
procedures, major orthopedic procedures of the hip or spinal
column, or major procedures of the neck (28). From January
1998 to February 2001, 183 patients were enrolled after
obtaining their informed written consent (approved by the
institutional review board at the University Hospital of
Basel, Switzerland). Ten (5%) of the enrolled patients were
excluded from further analysis: four patients had their
opera-tive procedures cancelled, three patients did not fulfill
all inclusion criteria, and in three patients Holter equipment
failure occurred.
Each patient’s history and preoperative data were col-
lected, and the following risk scores calculated: the modified
cardiac risk index published by Detsky and colleagues (6),
the clinical predictors according to the Guidelines for
Perioperative Cardiac Evaluation for Noncardiac Surgery of
the American College of Cardiology and the American
Heart Association (28), and the revised cardiac risk index
published by Lee et al. (8).
Renal failure was defined as serum creatinine 177 mol/l
( 2 mg/dl) (8). Diabetes mellitus was diagnosed if the
patient was treated with insulin and/or oral antidiabetic
agents. History of congestive heart failure was defined accord-
ing to Lee et al. (8). Arterial hypertension was diagnosed in
patients with concurrent antihypertensive therapy and in pa-
tients with systolic arterial pressure 160 mm Hg, and/or
diastolic arterial pressure 95 mm Hg at admission.
Measurements. All data were collected prospectively. The
entire perioperative management of the patients including
preoperative evaluation, anesthetic technique, and cardiac
and antihypertensive medication was guided by the physi-
cian in charge and not influenced by the study protocol. A
study physician examined all patients before surgery and
daily for the first six days after surgery.
Continuous electrocardiography (ECG) recordings
(Marquette Series 8500, Marquette Electronics, Milwau-
kee, Wisconsin) were started before induction of anesthesia
in the operating theatre and continued for the next 48 h.
Three bipolar leads (V5, inverse Nehb J, aVF) were recorded
(29). Tapes were processed on a computerized analyzer (Mar-
quette Laser SXP). ST-segment trend analysis was manually
reviewed on all three leads according to the published guide-
lines (30) by a physician blinded to all other study data.
For HRV measurements, the computer system classified
the QRS complexes as normal beats, ectopic beats (supra-
ventricular and ventricular), and artifacts. This classification
was controlled visually on a screen and corrected manually
when necessary. Special care was taken to eliminate from
further analysis ectopic beats or artifacts that had been
classified incorrectly as normal by the computer algorithm.
Heart rate variability subsequently was calculated using
commercially available software (Marquette, Version 5.8)
according to published guidelines (31).
Time domain measurements of HRV (SD of normal-
beat intervals, SD of the average of normal-beat intervals in
5-min segments of the entire recording, the square root of
the mean of the sum of the squares of the differences
between adjacent normal-beat intervals, and percent of
normal-beat intervals differing by more than 50 ms in the
entire recording) were calculated for the first and second
24-h period of recording according to current guidelines
(31). Frequency domain measurements of HRV were cal-
culated for both 24-h periods. In addition, short-term
periods of 6 min were calculated at the following time
points: baseline (immediately after start of the recording and
before induction of anesthesia), and at 9 AM of the first and
the second postoperative mornings. Using a fast Fourier
Abbreviations and Acronyms
CAD coronary artery disease
CI  confidence interval
cTnI  cardiac troponin I
ECG electrocardiography
HF  high-frequency power
HRV heart rate variability
LF  low-frequency power
OR  odds ratio
ROC receiver operating characteristics
TP  total power
Table 1. Inclusion Criteria
Known coronary artery disease
Previous myocardial infarction
Previous coronary revascularization
Previous percutaneous coronary intervention
Previous coronary artery bypass graft surgery
Scintigraphic evidence of myocardial perfusion defects
New regional wall-motion abnormalities during dobutamine
stress echocardiography
High risk of coronary artery disease
Typical angina
Current vascular surgery and the presence of at least two of the
following risk factors:
Age 70 yrs
Diabetes mellitus
History of stroke
Uncontrolled systemic hypertension
Low functional capacity (i.e., inability to climb one flight of
stairs with a bag of groceries)
Abnormal electrocardiography (left ventricular hypertrophy,
left bundle-branch block, ST-T abnormalities)
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transformation algorithm and a Hanning spectral window,
the powers of the following frequency bands were calcu-
lated: total power (TP), (0.01 to 1.0 Hz); low frequency
power (LF), (0.04 to 0.15); high frequency power (HF),
(0.15 to 0.4 Hz); and the LF/HF ratio. Measurements of
HRV were available in 148 of 173 (86%) patients and could
not be obtained in 25 patients, 19 of whom had atrial
fibrillation, three very frequent supraventricular premature
beats, and one a pacemaker-triggered heart rhythm, whereas
recordings could not be analyzed because of technical
problems in two patients.
Cardiac troponin I was measured before surgery, imme-
diately after arrival in the postanesthesia care unit, 8 h after
the end of surgery, daily for the first three days, and on day
6 after surgery. For cTnI analysis, a commercially available
kit (AxSYM, Abbott, Abbott Park, Illinois) was used with
the normal upper limit of 2 g/l specified by the
manufacturer.
Twelve-lead ECGs were performed preoperatively, post-
operatively after arrival in the postanesthesia care unit, and
on postoperative days 1 and 6. They were analyzed accord-
ing to the Minnesota criteria (32) by an investigator blinded
to all other study data.
Follow-up and outcome measurements. Semistructured
follow-up interviews were done by telephone 6 and 12 months
postoperatively to determine mortality and establish reasons for
death. All reported events were verified by the family physi-
cians of the patients or by a review of hospital charts. However,
the correct cause of death could not be unambiguously defined
in some patients who died outside of a hospital.
Statistical analysis. The Mann-Whitney U test was used
to compare HRV data. Differences in categorical variables
were assessed by the Fisher exact test. Cutoff values for
prediction of one-year all-cause mortality for cTnI and for
the LF/HF ratio were based on receiver operating charac-
teristics (ROC) (33). Potential univariate parameters of
adverse outcome were identified using logistic regression. A
first multivariate logistic regression analysis was performed
by entering baseline variables with an initial p value of
0.10 into the model. A second multivariate logistic re-
gression analysis was performed by entering into the model
the two investigated perioperative findings (cTnI elevation,
LF/HF depression) along with the baseline scoring that had
the highest prognostic power (revised cardiac risk index). In
addition, Kaplan-Meier survival curves were compared
with the log-rank test. All analyses were performed using
StatView computer package version 5.0 (SAS Institute Inc.,
Cary, North Carolina). A p value 0.05 was considered to
indicate a significant difference.
RESULTS
A total of 173 patients were included in the study; 57 (33%)
women, and 116 (67%) men. The median age was 73 years
Table 2. Baseline Characteristics, Long-Term Medication, Type of Surgery, Type of Anesthesia,
and Mortality After 30 Days and 1 Year
Number of Deaths
(Mortality) After
30 Days 1 Year
Age 73 (47–89)
Age 70 yrs 115 (66) 5 (4) 23 (20)
Female 57 (33) 3 (5) 11 (19)
Documented CAD (according to Table 1) 114 (66) 4 (4) 15 (13)
At high risk of CAD (according to Table 1) 59 (34) 2 (3) 13 (22)
Long-term medication
Beta-receptor blockers 59 (34) 1 (2) 7 (12)
Calcium antagonists 46 (27) 1 (2) 9 (20)
Angiotensin-converting enzyme inhibitors 61 (35) 4 (7) 11 (18)
Amiodarone 9 (5) 0 2 (22)
Digitalis 14 (8) 0 4 (29)
Diuretics 64 (37) 3 (5) 19 (30)
Oral antidiabetics 26 (15) 2 (8) 9 (33)
Insulin 16 (9) 0 4 (22)
Surgical procedures
Abdominal-aortic surgery 59 (34) 2 (3) 4 (7)
Peripheral-vascular surgery 55 (32) 3 (5) 14 (25)
Laparotomy 39 (23) 0 7 (18)
Major orthopedic surgery 14 (8) 0 2 (14)
Thoracotomy 4 (2) 1 (25) 1 (25)
Other major procedures 2 (1) 0 0
Anesthesia technique
General anesthesia 73 (42) 4 (5) 8 (11)
Regional anesthesia 32 (18) 2 (6) 10 (31)
Combined general and regional anesthesia 68 (39) 0 10 (15)
Median (range) or number of patients (%).
CAD  coronary artery disease.
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(range 47 to 89 years). Patients’ characteristics at baseline
are shown in Table 2. Follow-up data were available from all
patients. Six (3.5%) patients died within the first 30 post-
operative days, and 28 (16%) patients within one year.
Twelve of 28 deaths were considered to have cardiac causes,
14 of 28 noncardiac causes, and in 2 patients the cause of
death remained unclear.
The following variables were associated with death within
30 days: history of renal failure, revised cardiac risk index (8)
of IV, an LF/HF ratio2 before induction of anesthesia, an
elevation of cardiac troponin I 2 g/l or of creatine kinase
MB mass 10.4 g/l on postoperative day 1 or 2, and
electrocardiographic evidence of perioperative myocardial
ischemia (Table 3).
Using an univariate analysis, baseline variables associated
with death within one year were found to be history of renal
failure, congestive heart failure, arterial hypertension, and
diabetes mellitus (Table 4). Age 70 years showed a
marginally significant association with mortality (Table 4).
Patients’ classified as IV according to the revised cardiac risk
index (8) showed a marginally significant association with
one-year mortality (odds ratio [OR] 2.7, 95% confidence
interval [CI] 1.0 to 6.9, p  0.04; see Fig. 1A, for the
corresponding Kaplan-Meier survival curve).
If all vascular procedures had been counted as “high-risk
surgery” and not only suprainguinal vascular procedures
as originally described by Lee et al. (8), this expanded
revised cardiac index would have been highly predictive
Table 3. Risk Scores and Significant Univariate Predictors of Mortality After 30 Days
Number
of Patients
Mortality
(%) OR 95% CI 2 p
History of renal failure (serum creatinine
177 mol/l  2.0 mg/dl)
Yes 13 15 7.1 1.2–43 4.5 0.03
No 160 3
History of congestive heart failure Yes 23 9 3.5 0.6–20 1.9 0.16
No 150 0.7
History of arterial hypertension Yes 120 4 2.3 0.3–20 0.5 0.46
No 53 2
Diabetes mellitus (insulin or oral
antidiabetics)
Yes 42 5 1.6 0.3–8.9 0.3 0.6
No 131 3
Insulin alone* 16 0
Oral antidiabetics* 26 8
Age 70 yrs Yes 115 4 2.6 0.3–23 0.7 0.39
No 58 2
Risk scores
AHA clinical predictors
Minor 32 3
Intermediate 131 4 1.1 0.1–10 0.01 0.9
Major 10 0
Detsky score
Low 77 4
Intermediate 81 2 0.8 0.2–4.1 0.08 0.8
High 15 7
Revised cardiac risk index
I† 11 0
II† 46 4
III† 89 1
IV† 27 11 5.9 1.1–31 4.5 0.03
Regional anesthesia alone Yes 32 6 2.2 0.4–13 0.8 0.35
No 141 3
LF/HF 2 preoperatively‡ Yes 79 6 –§ 1.1– —§ —§
No 69 0
Troponin I 2.0 g/l on postoperative
day 1 or 2
Yes 27 19 33 3.7–296 9.8 0.002
No 146 0.7
CK-MB mass 10.4 g/l on postoperative
day 1 or 2
Yes 20 20 18.9 3.2–111 10.5 0.001
No 153 1
Electrocardiographic evidence of perioperative Yes 54 7 –§ 1.1– —§ —§
ischemia (48 h) No 63 0
*Five patients took both insulin and oral antidiabetics and none of them died; †0, 1, 2, 3 of the following findings indicates
class I, II, III, or IV, respectively: high-risk type of surgery (intrathoracic, intra-abdominal, or suprainguinal vascular procedures),
history of ischemic heart disease, history of congestive heart failure, history of cerebrovascular disease, preoperative treatment
with insulin, preoperative serum creatinine (2.0 mg/dl  177 mol/l); ‡Heart rate variability (HRV) measures could not be
performed in 25 of 173 patients because of atrial fibrillation (19 patients), very frequent premature beats (three patients),
pacemaker-triggered heart rhythm (one patient), technical problems (two patients); §Because, no events occurred in one group,
only a one-sided 95% confidence interval can be given; ST-segment analysis could not be performed in 54 of 173 patients
because of the presence of one or more findings of the following: baseline shift 0.1 mV, amplitude of R wave 1 mV,
dyscordant or negative T wave, Q wave 40 ms. In two other patients, equipment failure occurred.
AHA  American Heart Association; CI  confidence interval; CK-MB  MB-fraction of creatine kinase; HF 
high-frequency power of HRV; LF  low-frequency power of HRV; OR  odds ratio.
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of 12-month mortality (OR 3.1, 95% CI 1.3 to 7.1, p 
0.009).
In addition to the above-mentioned findings, HRV and
cTnI were strongly associated with death. In all analyzed
long- and short-term periods, the LF/HF ratio of survivors
was significantly higher compared with nonsurvivors.
Seventy-nine patients (53%) had an LF/HF ratio 2 in the
preoperative short-term measurement, 19 (24%) of whom
died. Sixty-nine patients (47%) had an LF/HF ratio 2,
two (3%) of whom died (Fig. 1B, for the corresponding
Kaplan-Meier survival curve). The area under the ROC
curve for LF/HF was 0.76. An LF/HF ratio 2 in the
baseline measurement was strongly associated with death
after one year (OR 10.6, 95% CI 2.4 to 48, p  0.0001).
The associations between one-year mortality and the
LF/HF ratios on the first and second postoperative morn-
ings were also significant but slightly weaker than that of the
baseline measurement (OR 4.6, 95% CI 1.3 to 17, p 0.02;
OR 6.3, 95% CI 1.4 to 29, p  0.02, respectively). In
addition to the LF/HF ratio, the SD of normal-beat
intervals, and the SD of the average of normal-beat intervals
in 5-min segments of the entire HRV recording were lower
in the first 24 h of recording in the patients who died
compared with those who survived. In the short-term
measurements, TP at baseline was lower in survivors com-
pared with nonsurvivors. All other HRV measurements
were statistically similar in these two groups. The LF/HF
ratio at baseline was lower in patients with a history of
congestive heart failure and in patients with renal failure.
However, no differences were found between patients with
or without diabetes, hypertension, or known or suspected
CAD.
Table 4. Risk Scores and Significant Univariate Predictors of First Year Mortality
Number of
Patients
Mortality
(%) OR 95% CI 2 p
History of renal failure (serum creatinine 177 mol/l
 2.0 mg/dl)
Yes 13 46 5.4 1.7–18 7.8 0.005
No 160 14
History of congestive heart failure Yes 23 35 3.5 1.3–9.2 6.2 0.013
No 150 8
History of arterial hypertension Yes 120 20 3.1 1.0–9.3 3.9 0.049
No 53 8
Diabetes mellitus (insulin or oral antidiabetics) Yes 42 26 2.5 1.0–5.6 3.9 0.038
No 131 13
Insulin alone* 16 13
Oral antidiabetics* 26 35
Age 70 yrs Yes 115 20 2.7 0.95–7.4 3.5 0.06
No 58 9
Risk scores
AHA clinical predictors
Minor 32 16
Intermediate 131 18 1.1 0.4–3.0 0.01 0.9
Major 10 0
Detsky score
Low 77 13
Intermediate 81 16 1.5 0.7–3.6 1.0 0.3
High 15 33
Revised cardiac risk index
I† 11 18
II† 46 20
III† 89 10
IV† 27 30 2.7 1.0–6.9 4.0 0.04
Regional anesthesia alone Yes 32 31 3.1 1.3–7.6 6.1 0.013
No 141 13
LF/HF 2 preoperatively‡ Yes 79 24 10.6 2.4–48 9.5 0.0001
No 69 3
Troponin I 2.0 g/l on postoperative day 1 or 2 Yes 27 44 6.5 2.6–16 15.9 0.0001
No 146 11
CK-MB mass 10.4 g/l on postoperative day 1 or 2 Yes 20 35 3.4 1.2–9.5 5.4 0.02
No 153 14
Electrocardiographic evidence of perioperative Yes 54 22 4.2 1.3–14 5.5 0.02
ischemia (48 h)§ No 63 6
*Five patients took both, insulin and oral antidiabetics, from whom two died within one year; †0, 1, 2, 3 of the following findings indicates class I, II, III, or IV, respectively:
high-risk type of surgery (intrathoracic, intra-abdominal, or suprainguinal vascular procedures), history of ischemic heart disease, history of congestive heart failure, history of
cerebrovascular disease, preoperative treatment with insulin, preoperative serum creatinine (2.0 mg/dl  177 mol/l); ‡Heart rate variability (HRV) measures could not be
performed in 25 of 173 patients because of atrial fibrillation (19 patients), very frequent premature beats (three patients), pacemaker-triggered heart rhythm (one patient), technical
problems (two patients); §ST-segment analysis could not be performed in 54 of 173 patients because of the presence of one or more findings of the following: baseline shift 0.1
mV, amplitude of R wave 1 mV, dyscordant or negative T wave, Q wave 40 ms. In two other patients, equipment failure occurred.
Abbreviations as in Table 3.
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Cardiac troponin I was elevated (2.0 g/l) on the first
and/or second postoperative mornings in 27 (16%) patients,
12 (44%) of whom died (Fig. 1C, for the corresponding
Kaplan-Meier survival curve). The area under the ROC
curve for cTnI elevation was 0.74. An elevation of cTnI
2 g/l on the first and/or second postoperative mornings
was strongly associated with 12-month all-cause mortality
(OR 6.5, 95% CI 2.6 to 16, p  0.0001). Cardiac troponin
I was elevated preoperatively in 6 patients (4 died), imme-
diately postoperatively in 6 patients (4 died), 8 h postoper-
atively in 9 patients (5 died), on the first postoperative
morning in 11 patients (7 died), on the second in 24 patients
(11 died), on the third in 22 patients (7 died), and on the
sixth in 13 patients (3 died). Cardiac troponin I was elevated
preoperatively, but not postoperatively, in only one patient
who had a good outcome.
Of the 27 patients who had a cTnI elevation on the first
and/or second postoperative mornings, 16 had an LF/HF
ratio 2 at baseline, of whom 10 patients (63%) died. In
contrast, only one patient (2%) died of the 62 patients who
did not have a cTnI elevation and had an LF/HF ratio 2.
Additional findings associated with one-year mortality
were regional anesthesia compared with general or com-
bined regional/general anesthesia, evidence of myocardial
ischemia in the Holter ECG recordings, and a rise in
creatine kinase MB mass. In contrast, gender, histories of
stroke, coronary revascularization, and myocardial infarction
or evidence of perioperative myocardial infarction in the
12-lead ECG were not associated with death. Separate
univariate logistic regression analysis results for patients
with documented CAD and patients with high risk for
CAD (defined according to Table 1) are summarized in
Table 5.
The first multivariate analysis revealed an LF/HF ratio
2.0 in the preoperative short-term analysis of HRV
(OR 13.7, 95% CI 1.9 to 97, p  0.009), elevated cTnI
2 g/l on postoperative day 1 or 2 (OR 10.2, 95% CI 2.8
to 37, p  0.0004), and history of congestive heart failure
Figure 1. Kaplan-Meier survival curves (considering death from all causes as end point) in patients with revised cardiac risk index IV or less (A), in patients
with low-frequency power of heart rate variability (HRV)/high frequency power of HRV (LF/HF ratio) before induction of anesthesia lower or higher than
2 (B), and in patients with or without elevation of cardiac troponin I on postoperative day 1 or 2 (C). (D) shows Kaplan-Meier survival curves of patients
having none or only one of these three risk indicators or of patients having two or all three of them. HF  high frequency power; LF  low frequency
power.
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(OR 7.0, 95% CI 1.4 to 35, p  0.02) as independent
predictors of 12-month all-cause mortality (Table 6A). A
second multivariate model (Tables 6B and 7), including the
revised cardiac risk index instead of the baseline variables in
the model, showed an unchanged impact resulting from
cTnI and the LF/HF ratio, and identified the risk index as
a third independent predictor of subsequent death (OR 6.2,
95% CI 1.6 to 25, p  0.01).
DISCUSSION
This study identifies three perioperative parameters as
independent predictors of all-cause mortality within one
year after major noncardiac surgery in patients with docu-
mented CAD or who were at a high risk of CAD. These
parameters are the revised cardiac risk index, the preopera-
tive LF/HF ratio, and a postoperative rise in cTnI. The
same parameters were also strongly associated with mortal-
ity within 30 days after surgery.
Clinical scores to predict risk. Established risk scores use
the patient’s history and the preoperative clinical status to
predict short-term outcome or to identify patients with the
need for more detailed cardiac testing (28). The revised
cardiac risk index (8) is the latest adaptation of the well-
established Goldman score (5). This revised cardiac risk
index (8) was a strong independent predictor of adverse
Table 6. Multivariate Analysis to Predict All-Cause
First-Year Mortality
A.
OR 95% CI 2 p
LF/HF 2 preoperatively 13.7 1.9–97 6.8 0.009
Troponin I 2.0 g/l on
postoperative day 1 or 2
10.2 2.8–37 12.4 0.0004
History of congestive heart failure 7.0 1.4–35 5.7 0.02
Age 70 yrs 4.2 1.0–19 3.6 0.06
HF  high-frequency power of heart rate variability (HRV); LF  low-frequency
power of HRV; OR  odds ratio..
B.
OR 95% CI 2 p
LF/HF 2 preoperatively 16.2 2.8–94 9.7 0.002
Troponin I 2.0 g/l on
postoperative day 1 or 2
9.8 3.0–32 14.3 0.0002
Revised cardiac risk index class IV 6.2 1.6–25 6.7 0.01
Abbreviations as in Table 3.
Table 5. Significant Univariate Predictors of First-Year Mortality in 114 Patients With Documented CAD and in 59 Patients With
High-Risk of CAD
CAD†
Number of
Patients (%)
Mortality
(%) OR 95% CI 2 p
History of renal failure (serum creatinine
177 mol/l  2.0 mg/dl)
Documented 8 (7) 50 8.6 1.9–40 7.7 0.005
At risk 5 (8) 40 2.6 0.4–18 1.0 0.3
History of congestive heart failure Documented 17 (15) 35 5.3 1.6–18 7.4 0.007
At risk 6 (10) 33 1.9 0.3–12 0.5 0.5
History of arterial hypertension Documented 73 (64) 11 2.5 0.7–9.4 1.8 0.2
At risk 47 (80) 26 3.8 0.4–32 1.5 0.2
Diabetes mellitus (insulin or oral antidiabetics) Documented 19 (17) 26 3.0 0.9–10 3.2 0.07
At risk 23 (39) 26 1.4 0.4–5.1 0.4 0.5
Age 70 yrs Documented 70 (61) 17 2.8 0.8–11 2.4 0.12
At risk 45 (76) 24 1.9 0.4–10.1 0.6 0.4
Risk scores
AHA clinical predictors
Intermediate or major Documented 102 (89) 14 1.8 0.2–15 0.3 0.6
At risk 39 (66) 23 1.2 0.3–4.5 0.1 0.8
Detsky score
Intermediate or high Documented 63 (55) 16 1.7 0.6–5.4 0.9 0.3
At risk 33 (56) 24 1.3 0.4–4.7 0.2 0.6
Revised cardiac risk index IV‡ Documented 22 (19) 32* 4.9 1.5–16 7.3 0.007
At risk 5 (8) 20* 0.9 0.1–8.6 0.01 0.9
LF/HF 2 preoperatively§ Documented 48 (48) 25 17.3 2.2–139 7.2 0.007
At risk 31 (66) 23 4.4 0.5–39 1.7 0.19
Troponin I 2.0 g/l on postoperative
day 1 or 2
Documented 16 (9) 38 5.9 1.7–20 8.2 0.004
At risk 11 (19) 55 7.0 1.7–29 7.1 0.008
CK-MB mass 10.4 g/l on postoperative
day 1 or 2
Documented 11 (10) 27 2.8 0.7–12 2.0 0.16
At risk 9 (15) 44 3.6 0.8–16 1.7 0.09
Electrocardiographic evidence of perioperative
ischemia (48 h)
Documented 34 (47) 24 11.4 1.3–97 5.0 0.03
At risk 20 (44) 20 1.8 0.3–9.4 0.5 0.5
*p  0.05 between mortality in patients with and without documented coronary artery disease (CAD); †CAD documented according to Table 1; ‡0, 1, 2, 3 of the following
findings indicates class I, II, III, or IV, respectively: high-risk type of surgery (intrathoracic, intra-abdominal, or suprainguinal vascular procedures), history of ischemic heart
disease, history of congestive heart failure, history of cerebrovascular disease, preoperative treatment with insulin, preoperative serum creatinine (2.0 mg/dl  177 mol/l);
§Heart rate variability (HRV) measures could not be performed in 13 of 114 patients with documented CAD and in 12 patients with high risk for CAD because of atrial
fibrillation (19 patients), very frequent premature beats (three patients), pacemaker-triggered heart rhythm (1 patient), technical problems (2 patients); ST-segment analysis could
not be performed in 42 patients with documented CAD and in 14 patients with high risk for CAD because of the presence of one or more findings of the following: baseline
shift 0.1 mV, amplitude of R wave 1 mV, dyscordant or negative T wave, Q wave 40 ms. In 2 other patients, equipment failure occurred.
Abbreviations as in Table 3.
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outcome in the multivariate analysis, and even was margin-
ally statistically significant in the univariate analysis. The
index was developed originally to predict short-term mor-
bidity and mortality (8). Therefore, application of this risk
score to predict long-term outcome may need some adap-
tations, mainly the definition of “high-risk surgery.” This
definition does not include infrainguinal vascular proce-
dures. This exclusion seems questionable because all pa-
tients undergoing vascular procedures are at a substantial
risk (34,35).
Our results confirm the prognostic value of comorbidities
such as history of renal insufficiency, congestive heart
failure, and diabetes for long-term prognosis. This is not
surprising because these diseases are elements of the revised
cardiac risk index.
HRV parameters to predict risk. Our study identifies an
LF/HF ratio 2 before induction of anesthesia as a strong
and independent predictor of all-cause mortality after one
year. In surgical patients, the prognostic value of HRV
measurements has been shown only for short-term outcome
in a small number of patients (27), but it has not been
evaluated for long-term outcome. In contrast, the prognos-
tic value of HRV in nonsurgical patients with acute myo-
cardial infarction and unstable angina has been established
in many studies (19,31,36). These studies consistently found
a reduction in one or several parameters of HRV in patients
with CAD compared with normal subjects (20,36). In
patients with acute myocardial infarction, reduced HRV
(e.g., a reduced LF/HF ratio [19]) predicted a worse
outcome (19,21,22,37). The reduction in HRV mainly is
explained by an imbalance of the sympathetic and parasym-
pathetic nervous system (22,31). Reduced HRV, evident as
a reduction in LF and the LF/HF ratio, was also found in
patients with heart failure (24–26), and is explained by a
central regulatory impairment (24). The reduced LF/HF
ratio before induction of anesthesia in many of our patients
and its strong association with subsequent bad outcome may
indicate the presence of (clinically silent) congestive heart
failure. The lower LF/HF ratio in patients with a history of
congestive heart failure may further support this explana-
tion. Postoperative HRV measurements did not provide
additional information to preoperative HRV measurements
for risk assessment, although the LF/HF ratio was predic-
tive of outcome at all analyzed time points. Because the
study recordings started only shortly before induction of
anesthesia, our data do not reveal the onset of HRV
reduction.
Cardiac markers to predict risk. As a third parameter, a
perioperative increase in cTnI was found to be highly
predictive of one-year mortality. This is in agreement with
the findings of Lopez-Jimenez et al. (4). They demon-
strated, in a study of 772 patients, a correlation between a
rise in cTnT and cardiac events within six months after
major noncardiac surgery (adjusted OR 4.6) (4). A recent
study by Kim et al. (18) reported the association of a
postoperative rise in cTnI with six-month mortality after
vascular surgical procedures. In agreement with results of
our study, both former studies found a strong association
between troponin elevation and six-month outcome; the
association was even stronger in our more selected popula-
tion. These studies are in accordance with results from
studies in nonsurgical patients with acute coronary syn-
dromes that also found a correlation between troponin
elevation and mortality (14,15). Accordingly, one can hy-
pothesize that a substantial percentage of cardiac risk
patients suffer during the perioperative period from the
equivalent of an acute coronary syndrome. This acute
coronary syndrome often remains clinically undetected but
provokes myocardial cell damage with a rise in troponin. As
in the nonsurgical population, myocardial ischemia with cell
damage is associated with a worse prognosis. A strong
association of perioperartive ischemia and long-term mor-
tality is well-established (3,4,10) and is also in agreement
with our findings.
The troponin analyses before surgery and on days 1 and
2 after surgery had the highest prognostic value and should
be considered as a component of perioperative risk assess-
ment. Further troponin analyses on the day of surgery and
analyses later than two days after surgery did not add
incremental predictive information.
Study limitations. Our study has some important limita-
tions. First, its sample size was relatively small, but large
Table 7. Incremental Value of HRV Measurement and cTnI in Predicting All-Cause Mortality
Revised Cardiac
Risk Index Mortality Mortality Mortality Mortality
I
18
LF/HF 2 0 cTnI 2 g/l 10 LF/HF 2 & cTnI 2 g/l 0
LF/HF 2 17 cTnI 2 g/l 100 cTnI 2 g/l & LF/HF 2 100
II 20
LF/HF 2 5 cTnI 2 g/l 12 LF/HF 2 & cTnI 2 g/l 5
LF/HF 2 27 cTnI 2 g/l 80 cTnI 2 g/l & LF/HF 2 80
III 11
LF/HF 2 3 cTnI 2 g/l 7 LF/HF 2 & cTnI 2 g/l 0
LF/HF 2 12 cTnI 2 g/l 31 cTnI 2 g/l & LF/HF 2 29
IV 27
LF/HF 2 0 cTnI 2 g/l 26 LF/HF 2 & cTnI 2 g/l 0
LF/HF 2 70 cTnI 2 g/l 38 cTnI 2 g/l & LF/HF 2 100
Data are percent mortality after 1 year of 173 patients (revised cardiac risk index and the cardiac troponin I [cTnI]) and 148 patients (heart rate variability [HRV] measurements).
LF  low-frequency power; HF  high-frequency power.
{ { {
{ { {
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enough to identify new independent risk predictors. How-
ever, these findings have to be confirmed in a second
prospectively studied large patient cohort. Second, our
results cannot be applied to patients with a lower risk profile
or to patients undergoing minor surgery, because we inves-
tigated patients at high risk of CAD. A further important
limitation is the timing of Holter recordings that were
started only 1 to 2 h before surgery. If a reduction in HRV
is used to identify patients at risk before surgery and to serve
as a basis for ameliorating their outcome, HRV measure-
ments should be performed days before surgery. In addition,
all HRV data in our study were calculated from Holter
recordings, a time-consuming process and not suitable for
daily routine. However, there are commercially available
ECG devices that perform frequency-domain analyses of
HRV on-line within 5 to 10 min. Whether such on-line
measurements contain the same prognostic information as
the Holter analysis in our study needs to be confirmed.
Conclusions. In conclusion, our study identified three
perioperative parameters as independent predictors of all-
cause mortality within one year after major noncardiac
surgery in patients with documented CAD or at high risk of
CAD. These parameters are the revised cardiac risk index
(8), representing the patient’s status and comorbidities; the
LF/HF ratio, representing the autonomic function imme-
diately preoperatively; and a rise in cTnI, representing
perioperative myocardial cell damage. The clinical value of
these findings needs to be assessed in future studies. These
studies will have to define concepts that use HRV and/or
troponin to identify surgical patients who may benefit from
(postoperative) cardiac reevaluation and optimization of
cardiac therapy.
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